Cancer cells can suppress immune responses, limiting the long-term effectiveness of immunotherapy. This research shows that monocytes—key immune cells—can be “trained” using metabolites to become more effective at attacking cancer. Understanding and harnessing this trained immunity could improve immunotherapy outcomes and help predict which patients benefit most from treatment.

Pancreatic ductal adenocarcinoma resists immunotherapy by building an immune-suppressive tumor fortress. This research explores how specific bacteria found in long-term survivors may reshape the tumor microenvironment, enhance immune checkpoint therapy, and help immune cells overcome suppression to attack pancreatic cancer more effectively.